Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2.
BNT162B2
Basophil activation test
CD63
PEGylated lipid nanoparticles
polyethylene glycol allergy
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
31 Dec 2024
31 Dec 2024
Historique:
medline:
6
2
2024
pubmed:
6
2
2024
entrez:
6
2
2024
Statut:
ppublish
Résumé
Basophil activation test (BAT) with COVID-19 mRNA vaccine seems particularly suitable for detecting sensitization to polyethylene glycol (PEG) in patients with PEG allergy. It was the aim of this study to determine the cutoffs for BAT using BNT162B2 (Comirnaty®) in a larger group of PEG allergic patients and controls. 10 PEG allergic patients and 10 controls were studied. BAT was performed using anti-CCR3 for basophil identification and anti-CD63 to assess basophil activation. Incubations with BNT162B2 at four different concentrations were performed. Basophil activation was significantly higher in PEG allergic patients compared to controls at the higher concentrations used. ROC curves showed best results with a sensitivity of 60% and specificity of 100% with a cutoff of 5% CD63
Identifiants
pubmed: 38317419
doi: 10.1080/21645515.2024.2312600
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM